Genmab

Genmab logo
🇩🇰Denmark
Ownership
Public
Employees
2.2K
Market Cap
$17.7B
Website
http://www.genmab.com
benzinga.com
·

Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry

Regeneron Pharmaceuticals' PE, PB, and PS ratios are low, suggesting potential undervaluation. However, its low ROE indicates lower profitability. High EBITDA and gross profit levels indicate strong financial performance, but low revenue growth may be a concern.
drugs.com
·

BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma

BioNTech announces positive Phase 2 results for mRNA immunotherapy BNT111 in advanced melanoma patients, showing significant improvement in ORR when combined with cemiplimab vs. historical control, with both monotherapies active. BNT111, part of BioNTech's FixVac platform, targets four tumor-associated antigens and has received FDA Fast Track and Orphan Drug designations for melanoma treatment.
© Copyright 2024. All Rights Reserved by MedPath